Pre-Clinical Evaluation of IRE1beta as a Novel Therapeutic Target for Cystic Fibrosis Airway Mucus Production
Pre-Clinical Evaluation of IRE1beta as a Novel Therapeutic Target for Cystic Fibrosis Airway Mucus Production
批准号:
10675710
负责人:
Carla Maria Pedrosa Ribeiro
金额:
$46.46万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-09-15 至 2025-08-31
关键词:
AddressAffectAirway DiseaseAmino AcidsAnti-Inflammatory AgentsAsthmaBacterial InfectionsBindingBinding ProteinsBirthBronchiectasisBronchiolitisCellsChildChronicClinicCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorCytoplasmCytoplasmic TailDataDistalEndoplasmic ReticulumEnzymesEpitheliumExhibitsFeedbackGastrointestinal tract structureGenerationsGeneticHumanImpairmentInflammationInositolIntegral Membrane ProteinInterleukinsMAPK8 geneMUC5AC geneMUC5B geneMammalsMediatingMedicalMessenger RNAModelingMucinsMucous body substanceMusObstructionPara-Influenza Virus Type 1Pathway interactionsPhosphotransferasesPreclinical TestingProductionProtein IsoformsProteinsPulmonary Cystic FibrosisRNA SplicingRegulationRespiratory Syncytial Virus InfectionsRespiratory SystemRespiratory syncytial virusRibonucleasesRoleSignal PathwayTNF geneTertiary Protein StructureTestingTherapeutic EffectVX-770Viral BronchiolitisVirulence FactorsVirus Diseasesairway epitheliumairway inflammationaspiratebronchial epitheliumcystic fibrosis airwaycystic fibrosis airway epitheliacystic fibrosis mousecystic fibrosis patientscytokineefficacy testingendoplasmic reticulum stressidiopathic pulmonary fibrosisinfant infectioninhibitorinnovationmutantneutrophilnew therapeutic targetnovel therapeuticsoverexpressionp38 Mitogen Activated Protein Kinasepharmacologicpreclinical evaluationpreventrespiratory infection virusresponsesensortargeted treatmenttranscription factor
中文摘要
囊性纤维化(CF)肺在出生后不久就表现出粘膜炎症反应,可能是由病毒引起的。
感染和/或吸入。呼吸道合胞病毒(RSV)引起毛细支气管炎,导致气道粘膜炎。
在婴幼儿CF儿童中,气道中MUC 5 B和MUC 5AC粘蛋白增加。
由于CF气道粘液过度产生没有治疗方法,因此存在明显的未满足的医疗需求
用于靶向CF气道中粘蛋白合成的治疗。CF气道上皮炎症触发内质网
内质网(ER)应激并激活肌醇需要酶1(IRE 1),该酶以两种亚型存在,α和
β。IRE 1 α是普遍存在的,但IRE 1 β仅在呼吸道和胃肠道的粘液细胞中表达。我们有
显示IRE 1 β(而不是IRE 1 α)是气道粘蛋白产生所必需的。IRE 1是ER跨膜蛋白
具有内腔结构域(未折叠蛋白的传感器)和具有激酶和RNA酶的胞质结构域(效应器
活动目前还不清楚IRE 1的胞内结构域是否能感知未折叠的粘蛋白,以及其胞质内结构域是否能感知未折叠的粘蛋白。
结构域介导粘蛋白的产生,然而,我们以前的研究表明,粘蛋白的产生触发ER
应激并激活IRE 1 β激酶诱导的RNase激活。因为激活的IRE 1 β RNA酶将
X-box结合蛋白-1(XBP-1 s)是一种上调粘蛋白产生的转录因子,
提供CF气道上皮粘蛋白过度产生的机制。在非粘液细胞中,IRE 1 β激酶激活
JNK、p38 MAP激酶和NF-κ B B通过蛋白质相互作用,但不清楚IRE 1 β激酶是否激活
这些途径与CF气道相关,因为它们可以促进粘蛋白的产生。我们的初步
数据表明,IRE 1 β、MUC 5AC和MUC 5 B水平在天然CF人气道中上调,
新鲜分离的CF人远端气道上皮细胞。野生型IRE 1 β在人原代支气管上皮细胞中的过表达
上皮细胞(HBE)增加粘蛋白的产生,而IRE 1的过度表达使缺乏激酶和/或
核糖核酸酶活性降低粘蛋白的产生。IL-1 β和TNF α是CF气道的主要细胞因子,
影响HBE中的XBP-1 s(仅IL-1 β增加XBP-1 s)和粘蛋白产生(IL-1 β> TNF β),表明
它们通过IRE 1 β RNase依赖性和非依赖性机制上调粘蛋白的产生。KIRA6,IRE1
激酶+RNA酶抑制剂,钝化IL-1 β-增加CF HBE中的XBP-1和粘蛋白。值得注意的是,
CFTR调节剂(VX-445、VX-661和VX-770)对粘蛋白产生没有影响。乙型肝炎病毒感染
增加XBP-1和粘蛋白的产生/分泌,并且这些反应被KIRA 6钝化。最后,鼠
副流感病毒1型感染的小鼠发生病毒性细支气管炎和气道粘膜阻塞,
RSV感染CF婴儿的毛细支气管炎。我们的目的是检测IRE 1 β蛋白结构域在CF气道中的作用。
甜菜碱增加CF HBE中的粘蛋白产生。我们还将评估IRE 1 β抑制剂的治疗效果。
对CF HBE和小鼠气道(包括CF小鼠)中呼吸道病毒感染诱导的粘蛋白产生的影响。
我们的研究可能导致IRE 1 β抑制剂的产生,作为CF气道粘膜阻塞的新疗法。
英文摘要
Cystic fibrosis (CF) lungs exhibit mucoinflammatory responses soon after birth, likely triggered by viral
infections and/or aspiration. Respiratory syncytial virus (RSV) causes bronchiolitis leading to airway muco-
obstruction in young CF children, who exhibit increases in MUC5B and MUC5AC mucins in their airways.
Because no treatments are available for CF airway mucus overproduction, there is a clear unmet medical need
for therapies that target mucin synthesis in CF airways. CF airway epithelial inflammation triggers endoplasmic
reticulum (ER) stress and activates the inositol requiring enzyme 1 (IRE1), which exists in two isoforms, α and
β. IRE1α is ubiquitous, but IRE1β is only expressed in mucous cells of the respiratory and GI tracts. We have
shown that IRE1β (but not IRE1α) is required for airway mucin production. IRE1 is an ER transmembrane protein
with a lumenal domain (sensor of unfolded proteins) and a cytoplasmic domain (effector) with kinase and RNase
activities. It is unknown whether the IRE1 lumenal domain senses unfolded mucins and whether its cytoplasmic
domains mediate mucin production; however, our previous studies suggested that mucin production triggers ER
stress and activates IRE1β kinase-induced RNase activation. Because the activated IRE1 RNase splices the
mRNA of X-box binding protein-1 (XBP-1s), a transcription factor that up-regulates mucin production, this may
provide a mechanism for CF airway epithelial mucin overproduction. In non-mucous cells, IRE1 kinase activates
JNK, p38 MAP kinase and NF-B via protein interactions, but it is unknown whether the IRE1 kinase activates
these pathways, which are relevant to CF airways because they can promote mucin production. Our preliminary
data indicate that IRE1β, MUC5AC and MUC5B levels are up-regulated in native CF human airways and in
freshly isolated CF human distal airway epithelia. Over-expression of wild type IRE1 in primary human bronchial
epithelia (HBE) increased mucin production, whereas over-expression of IRE1 mutants that lack kinase and/or
RNase activities decreased mucin production. IL-1 and TNF, predominant CF airway cytokines, differently
affected XBP-1s (only IL-1 increased XBP-1s) and mucin production (IL-1 > TNF) in HBE, suggesting that
they up-regulate mucin production via IRE1β RNase-dependent and independent mechanisms. KIRA6, an IRE1
kinase + RNase inhibitor, blunted IL-1-increased XBP-1s and mucins in CF HBE. Notably, a combination of
CFTR modulators (VX-445, VX-661 and VX-770) had no effect on mucin production. RSV infection of HBE
increased XBP-1s and mucin production/secretion, and these responses were blunted by KIRA6. Finally, murine
parainfluenza virus type 1-infected mice developed viral bronchiolitis and airway muco-obstruction, modeling the
bronchiolitis in CF infants infected by RSV. Our aims will test the role of IRE1β protein domains in CF airway
cytokine-increased mucin production in CF HBE. We will also evaluate the therapeutic effect of IRE1β inhibition
on respiratory virus infection-induced mucin production in CF HBE and murine airways, including a CF mouse.
Our studies may lead to the generation of IRE1β inhibitors as novel therapeutics for CF airway muco-obstruction.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.3390/ijms24055010
发表时间:
2023-03-05
期刊:
International journal of molecular sciences
影响因子:
5.6
作者:
[]
通讯作者:
Pre-Clinical Evaluation of IRE1beta as a Novel Therapeutic Target for Cystic Fibrosis Airway Mucus Production
-
批准号:10296058
-
项目类别:
-
资助金额:$46.46万
-
财政年份:2021
-
负责人:Carla Maria Pedrosa Ribeiro
-
依托单位:
IRE1beta: A Novel Pathway for Regulation of Airway Epithelial Mucin Production
-
批准号:8089547
-
项目类别:
-
资助金额:$18.5万
-
财政年份:2010
-
负责人:Carla Maria Pedrosa Ribeiro
-
依托单位:
IRE1beta: A Novel Pathway for Regulation of Airway Epithelial Mucin Production
-
批准号:7960927
-
项目类别:
-
资助金额:$22.2万
-
财政年份:2010
-
负责人:Carla Maria Pedrosa Ribeiro
-
依托单位:
海外基金